News Archive // Chi-Med

Please see http://meetinglibrary.asco.org/content/109556 The associated abstract is available at http://meetinglibrary.asco.org/content/148945-156. Meeting: 2015 ASCO Annual Meeting Session: Developmental Therapeutics – Clinical Pharmacol

2015 Interim Results Presentation

2015 Deutsche Bank Healthcare Conference (Boston)

ASCO 2015: Preliminary results of TATTON, a multi-arm Phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 (savolitinib) or selumetinib in EGFR-mutant lung cancer

Overview of Chi-Med

2014 Full Year Results Presentation

2015 JP Morgan Healthcare Conference (San Francisco)

Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1,2,3 tyrosine kinases for cancer therapy (Cancer Biology & Therapy 2014)

ACR/ARHP 2014: HM-0523 (HMPL-523), a novel Syk inhibitor, blocks glomerulonephritis and extends life spans in lupus prone MRL/lpr mice

2014 R&D Briefing

Discovery of [savolitinib] as a Highly Potent and Selective Mesenchymal-Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer (Journal of Medicinal Chemistry 2014)

2014 Interim Results Presentation

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors

ASCO 2014: First-in-Human Phase I study of a selective c-Met inhibitor AZD6094 (savolitinib) in patients with advanced solid tumors

AACR 2014: Discovery and Early Development of HMPL-504 (savolitinib)

AACR 2014: Targeting MET in preclinical models to support the clinical development of AZD6094/HMPL-504 (savolitinib) in NSCLC

AACR 2014: Anti-tumour activity of Epitinib in patient derived esophagus cancer models

2013 Full Year Results Presentation

ACR 2013: HMPL-523, a novel Syk inhibitor, significantly ameliorates the severity of arthritis in rodents

2013 R&D Briefing

2013 Interim Results Presentation

AACR 2013: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor -1, -2, and -3 tyrosine kinases in patients with advanced solid tumors

AACR 2013: Preclinical disposition and pharmacokinetics of savolitinib, a novel selective cMet inhibitor

AACR 2013: Synergistic effect of c-Met inhibitor savolitinib in combination with EGFR inhibitor Gefitinib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquired Met gene amplification

AACR 2013: HMPL-504 (savolitinib), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer

2012 Full Year Results Presentation

HMPL-004 (Andrographis paniculata extract) Prevents Development of Murine Colitis by Inhibiting T-cell Proliferation and TH1/TH17 Responses (Inflammatory Bowel Diseases 2013)

Chi-Med/Nestlé Health Science Analyst Conference Call Transcript

ISSX 2012: Pharmacokinetic/Pharmacodynamic Modeling of Epitinib to Evaluate the Anti-cancer Effect on A431 Tumor Xenograft in Nude Mice

Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis (American Journal of Gastroenterology 2013)

ASCO 2012: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors

ASCO 2012: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors

AACR 2011: Savolitinib (HMPL-504) against subcutaneous xenograft and orthotopic brain tumor models

Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis – a double-blind comparison with sustained release mesalazine (Alimentary Pharmacology and Therapeutics 2011)

ISSX 2011: Preclinical assessment of the absorption, distribution, metabolism and excretion of HMPL-013 (fruquintinib), a novel potent and specific VEGFR inhibitor